🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

First Hospital of China Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with First Hospital of China Medical University as lead sponsor. Synced 26 Sep 2026
25Current trials
16Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

First Hospital of China Medical University is the lead sponsor of 25 current clinical trials in our China register. 16 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Hydrogen Peroxide, 68Ga-NODAGA-SNA006 and Lenvatinib. The most-studied condition is Warts.

ClinicalTrials.gov trials by status

  • Recruiting1664%
  • Not yet open416%
  • Active, closed416%
  • By invitation14%

Trials by phase

  • Observational1144%
  • Not applicable1040%
  • Phase 1/214%
  • Phase 414%
  • Phase 314%
  • Phase 214%
01

Clinical trials sponsored by First Hospital of China Medical University

25 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
NCT06696417 · ClinicalTrials.gov ↗ · Moderate to Severe Plaque Psoriasis
Observational Recruiting 2025-02 China
Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts
NCT06812065 · ClinicalTrials.gov ↗ · Warts
Not applicable Recruiting 2022-12 China
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
NCT06632093 · ClinicalTrials.gov ↗ · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
Observational Recruiting 2024-09 China
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
NCT07503652 · ClinicalTrials.gov ↗ · Palmoplantar Pustulosis (PPP)
Phase 4 Recruiting 2026-03 China
Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis
NCT06300138 · ClinicalTrials.gov ↗ · Sporotrichosis
Not applicable Recruiting 2024-03 China
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
NCT07040306 · ClinicalTrials.gov ↗ · Graves´ Disease
Observational Recruiting 2012-11 China
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
NCT06282796 · ClinicalTrials.gov ↗ · Breast Cancer
Observational Recruiting 2024-01 China
First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2
NCT07593209 · ClinicalTrials.gov ↗ · Malignant Tumor
Observational Recruiting 2026-05 China
Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer
NCT06637215 · ClinicalTrials.gov ↗ · Colorectal Carcinoma, Day Surgery
Not applicable Recruiting 2023-11 China
Nutritional Intervention for Patients With Multiple Cancer Types
NCT06059560 · ClinicalTrials.gov ↗ · Cancer
Not applicable Recruiting 2023-10 China
Multicenter Real-World Study of Hyperthermia in Warts of Special Population
NCT06827938 · ClinicalTrials.gov ↗ · Warts
Not applicable Recruiting 2024-07 China
The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation
NCT07085650 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF), Mitral Regurgitation, Tricuspid Regurgitation
Observational Recruiting 2024-12 China
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
NCT07133516 · ClinicalTrials.gov ↗ · Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, Cardiovascular Diseases (CVD)
Observational Recruiting 2025-07 China
Local Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts
NCT07565350 · ClinicalTrials.gov ↗ · Refactory Warts
Not applicable Recruiting 2025-10 China
Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts
NCT07534865 · ClinicalTrials.gov ↗ · Warts
Not applicable Recruiting 2026-05 China
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
NCT07483359 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus
Phase 2 Recruiting 2026-05 China
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
NCT07292896 · ClinicalTrials.gov ↗ · Healthy Adults, Pulmonary Hypertension, Tricuspid Regurgitation
Observational Not yet open 2025-12 China
Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window
NCT07476898 · ClinicalTrials.gov ↗ · Stroke
Phase 3 Not yet open 2026-03 China
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065 · ClinicalTrials.gov ↗ · CRT Non-Response, LBBB, HF - Heart Failure
Observational Not yet open 2026-01 China
Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study
NCT07286812 · ClinicalTrials.gov ↗ · Alzheimer Disease
Observational Not yet open 2025-12 China
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
NCT07059819 · ClinicalTrials.gov ↗ · Cervical Intraepithelial Neoplasia (CIN), Human Papillovirus
Not applicable By invitation 2024-11 China
LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia
NCT07350486 · Hypertension, Diabetes, Dyslipidemia
Not applicable Active, closed 2026-05 China
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
NCT07059832 · ClinicalTrials.gov ↗ · Cancer
Phase 1/2 Active, closed 2024-04 China
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
NCT06632106 · ClinicalTrials.gov ↗ · Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors
Observational Active, closed 2024-08 China
China Rural Hypertension Control Project
NCT03527719 · ClinicalTrials.gov ↗ · Hypertension
Not applicable Active, closed 2018-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in First Hospital of China Medical University trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in First Hospital of China Medical University trials

40 conditions
Warts3Hypertension2Cancer2Tricuspid Regurgitation2Hepatic Arterial Infusion Chemotherapy2Hepatocellular Carcinoma (HCC)2Diabetes1Dyslipidemia1Moderate to Severe Plaque Psoriasis1Healthy Adults1Pulmonary Hypertension1Heart Failure1BCLC Stage B Hepatocellular Carcinoma1BCLC Stage C Hepatocellular Carcinoma1Lenvatinib1Palmoplantar Pustulosis (PPP)1Stroke1Cervical Intraepithelial Neoplasia (CIN)1Human Papillovirus1Sporotrichosis1CRT Non-Response1LBBB1HF - Heart Failure1Healthy Adult1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2516

A trial with sites in more than one country appears in each of those registers.

05

Questions about First Hospital of China Medical University trials

How many clinical trials does First Hospital of China Medical University sponsor?

First Hospital of China Medical University is the lead sponsor of 25 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are First Hospital of China Medical University trials recruiting?

Yes. 16 of its 25 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is First Hospital of China Medical University testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Hydrogen Peroxide (2), 68Ga-NODAGA-SNA006 (1), Lenvatinib (1), Methimazole (1) and Tenecteplase (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.